Skip to content
Screener

Allogene Therapeutics ALLO Financing Cash Flow

Financing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$2.63B-43.2%
Gilead Sciences logo
Gilead SciencesGILD
-$4.24B-23.7%
Precigen logo
PrecigenPGEN
$109K+116%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$591.91M+5,490%
Sana Biotechnology logo
Sana BiotechnologySANA
-$128K-113%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$283.27M

Other financials

Income statement

See full
Revenue-
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total equity$278.9M-27.6%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation

See full
Market cap$693.76M+205%
Enterprise value$734.21M+192%

Profitability

See full
Operating margin-1,241,813.6%-2,018,140pp
Net margin-1,170,863.6%-2,007,890pp
FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-034585
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from CIRM award (Note 5)3,350
Proceeds from issuance of common stock upon exercise of stock options4
Proceeds from issuance of common stock under the employee stock purchase plan450638
Net cash provided by financing activities21,12213,990
Net change in cash and cash equivalents and restricted cash(21,379)(32,763)
Cash and cash equivalents and restricted cash — beginning of period61,98085,510
Cash and cash equivalents and restricted cash — end of period$40,601$52,747
Non-cash operating activities:

Item 1. Financial Statements - Unaudited

FAQ

What is Allogene Therapeutics's financing cash flow?
Allogene Therapeutics (ALLO) reported financing cash flow of $21.12M in Q1 2026.
How has Allogene Therapeutics's financing cash flow changed year-over-year?
Allogene Therapeutics's financing cash flow increased by 51.0% year-over-year, from $13.99M to $21.12M.
What is the long-term trend for Allogene Therapeutics's financing cash flow?
Over 4 years (2021 to 2025), Allogene Therapeutics's financing cash flow has grown at a 26.0% compound annual growth rate (CAGR), from $11.96M to $30.16M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Allogene Therapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude